# Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06334432/  
OnCo record `nct06334432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of NUV-1511 in prostate cancer, pancreatic ductal adenocarcinoma and ovarian cancer, run by Nuvation Bio Inc., active and no longer recruiting.

## Summary

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06334432 by Nuvation Bio Inc., with 466 participants enrolled, started 2024-03-14 and due to reach its primary completion in 2027-03. Interventions recorded: NUV-1511.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06334432
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human, Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
- Sponsor: Nuvation Bio Inc.
- Enrolled: 466

## Sources

- ClinicalTrials.gov NCT06334432: https://clinicaltrials.gov/study/NCT06334432

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Nuvation Bio](https://onco.cc/companies/nuvation-bio/)
- drugs: [NUV-1511](https://onco.cc/drugs/nuv-1511/)

---
JSON: https://onco.cc/api/v1/entities/nct06334432.json